AI can generate more ideas, more quickly and at lower cost. But when every pharma brand has access to similar capabilities, speed alone is unlikely to create differentiation.
That is the question at the heart of Don’t Automate to Differentiate, a whitepaper jointly authored by Indegene and Impatient Health. Through the lens of Agentic AOR, the paper explores how AI can transform the traditional agency model while making human judgement, brand-specific evidence and continuous learning even more important.
The opportunity with AI is often framed around productivity: creating content faster, exploring more possibilities and accelerating activities that once required lengthy development cycles.
But simply adding AI to individual tasks does not necessarily change the underlying agency model.
This is where Agentic AOR represents a broader shift. Indegene describes Agentic AOR as an AI-native operating model where clients, senior creative directors and strategists work with AI agents in real time. Rather than adding AI to a traditional agency structure, the model shifts commercial execution toward AI-first, human-refined operations.
The model brings together four elements: senior human leadership, specialized life sciences agents, a governed knowledge foundation and a continuous feedback loop. Human experts continue to set direction, exercise judgement and protect brand and scientific integrity, while specialized agents support activities across the commercial lifecycle.
The whitepaper brings this new way of working to life through an AI-assisted campaign development exercise, where a process that would traditionally take considerably longer was compressed into a three-day workshop. AI helped teams rapidly explore and iterate campaign directions, while human expertise remained central to deciding which ideas were strategically relevant and worth pursuing.
The important shift is not simply from slower to faster execution.
It is from spending time creating a limited number of possibilities to spending more time evaluating which possibilities matter.
As access to powerful AI becomes widespread, technology alone is unlikely to create lasting differentiation.
If competing brands can use similar models to generate content and explore ideas, advantage increasingly depends on what each organization brings into the process.
Don’t Automate to Differentiate highlights the importance of behavioural data, a distinctive point of view, brand-specific evidence and content that works for both people and machines.
AI can expand the range of possibilities. But human judgement is still required to determine which idea reflects the strategy, which evidence supports it and which direction the brand can credibly own.
AI can generate options. It does not make every brand distinctive simply by being deployed.
This points to a bigger opportunity with Agentic AOR.
Organizations can use AI simply to produce the same outputs more efficiently. Or they can use the capacity it creates to explore more possibilities, challenge assumptions earlier and learn from each cycle.
The whitepaper argues for bringing important decisions forward and building feedback loops so what teams learn can inform what happens next.
That changes the conversation from how much time AI can save to how much more an organization can learn in that time.
As execution becomes easier to automate, differentiation may increasingly depend on the quality of the inputs, learning and human judgement surrounding AI.
And that may be where the real potential of Agentic AOR lies: not simply in using AI to automate the traditional agency model, but in rethinking the model so AI can accelerate the work while people focus their expertise where it matters most: making better decisions.
Don’t Automate to Differentiate, jointly authored by Indegene and Impatient Health, explores this shift in greater depth and what Agentic AOR could mean for the future of pharma marketing.